Breaking News

Crown Bioscience, ERS Genomics Ink Global CRISPR/Cas9 Licensing Agreement

Crown Bioscience will expand its gene editing capabilities and investigate the prospect of gene editing in 3D patient-derived tumor organoid models.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Crown Bioscience, Inc and ERS Genomics Ltd. have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CRISPR/Cas9 for gene editing. Financial details were not disclosed.   Crown Bioscience is a global CRO supporting drug discovery and development for oncology, immuno-oncology, and immune-mediated inflammatory diseases, providing preclinical and translational services to pharm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters